Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 May;36(5):335-47.
doi: 10.1007/s40264-013-0042-x.

Results From the First Decade of Research Conducted by the Research on Adverse Drug Events and Reports (RADAR) Project

Free PMC article

Results From the First Decade of Research Conducted by the Research on Adverse Drug Events and Reports (RADAR) Project

June M McKoy et al. Drug Saf. .
Free PMC article


Introduction: In 1998, a multidisciplinary team of investigators initiated the Research on Adverse Drug events And Reports (RADAR) project, a post-marketing surveillance effort that systematically investigates and disseminates information describing serious and previously unrecognized serious adverse drug and device reactions (sADRs).

Objective: Herein, we describe the findings, dissemination efforts, and lessons learned from the first decade of the RADAR project.

Methods: After identifying serious and unexpected clinical events suitable for further investigation, RADAR collaborators derived case information from physician queries, published and unpublished clinical trials, case reports, US FDA databases and manufacturer sales figures.

Study selection: All major RADAR publications from 1998 to the present are included in this analysis.

Data extraction: For each RADAR publication, data were abstracted on data source, correlative basic science findings, dissemination and resultant safety information.

Results: RADAR investigators reported 43 serious ADRs. Data sources included case reports (17 sADRs), registries (5 sADRs), referral centers (8 sADRs) and clinical trial reports (13 sADRs). Correlative basic science findings were reported for ten sADRs. Thirty-seven sADRS were described as published case reports (5 sADRs) or published case-series (32 sADRs). Related safety information was disseminated as warnings or boxed warnings in the package insert (17 sADRs) and/or 'Dear Healthcare Professional' letters (14 sADRs).

Conclusion: An independent National Institutes of Health-funded post-marketing surveillance programme can supplement existing regulatory and pharmaceutical manufacturer-supported drug safety initiatives.

Similar articles

See all similar articles

Cited by 4 articles

MeSH terms

LinkOut - more resources